MARKETS / BALCAO / GTHP
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Guided Therapeutics, Inc. GTHP

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$767,000
▲ 10857.1% vs FY2024
EPS · FY25
$-0.04
Dividend / sh · FY25
Payout · FY25
ROE · FY25
Net margin · FY25
-416.7%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 767,000.00
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.0010.0020.0030.0040.0-0.0201020132016201920222025
0.0010.0020.0030.0040.0-0.02016201920222025

The company lost 417 cents on every revenue dollar this year.

Per share
USD -0.04
Diluted EPS, FY2025
EPS
0.40.81.2-0.04201020132016201920222025
0.40.81.2-0.042016201920222025

The company pays no cash dividend.

Profitability
Return on equity, FY2025
ROE
0.250.50.751201020132016201920222025
0.250.50.7512016201920222025
Operating margin-309.3%
Net margin-416.7%
Return on assets-236.6%

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+49.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+289.3%
+49.7%
+33.7%
−9.4%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.09B
Shares outstanding, FY2025
0.000.09201020132016201920222025
0.000.092016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.3M
total assets, end of FY2025
Total assetsUSD 1.3M
EquityUSD -6.0M
CashUSD 63,000.00
Current ratio0.09×

Equity funds -454% of total assets.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.04
−0.05
−0.07
−0.15
−0.18
−0.04
−0.58
0.01
0.00
−24.62
−5939.38
−13.02
−0.16
−0.08
−0.14
−0.12
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
−1406.4
−321.3
−513.1
−280.9
Shares out B
0.09
0.07
0.05
0.05
0.01
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
56 of 63
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 3 failures and 4 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed